The Boston Advisors LLC Acquires 28,096 Shares of CVS Health Corporation (CVS)

The Boston Advisors LLC Acquires 28,096 Shares of CVS Health Corporation (CVS)

Boston Advisors LLC increased its position in CVS Health Corporation (NYSE:CVS) by 6.7% during the second quarter, Holdings Channel reports. The firm owned 446,163 shares of the pharmacy operator’s stock after buying an additional 28,096 shares during the period. CVS Health Corporation comprises about 1.1% of Boston Advisors LLC’s investment portfolio, making the stock its 12th largest position. Boston Advisors LLC’s holdings in CVS Health Corporation were worth $42,716,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. East Coast Asset Management LLC. boosted its stake in shares of CVS Health Corporation by 0.3% in the first quarter. East Coast Asset Management LLC. now owns 2,424 shares of the pharmacy operator’s stock worth $251,000 after buying an additional 8 shares during the last quarter. Palladium Partners LLC boosted its stake in shares of CVS Health Corporation by 1.0% in the second quarter. Palladium Partners LLC now owns 3,724 shares of the pharmacy operator’s stock worth $356,000 after buying an additional 38 shares during the last quarter. Harvest Capital Management Inc. boosted its stake in shares of CVS Health Corporation by 0.8% in the second quarter. Harvest Capital Management Inc. now owns 5,195 shares of the pharmacy operator’s stock worth $497,000 after buying an additional 40 shares during the last quarter. Adirondack Trust Co. boosted its stake in shares of CVS Health Corporation by 0.4% in the second quarter. Adirondack Trust Co. now owns 13,787 shares of the pharmacy operator’s stock worth $1,320,000 after buying an additional 50 shares during the last quarter. Finally, St. Johns Investment Management Company LLC boosted its stake in shares of CVS Health Corporation by 0.5% in the second quarter. St. Johns Investment Management Company LLC now owns 11,401 shares of the pharmacy operator’s stock worth $1,092,000 after buying an additional 58 shares during the last quarter. 80.96% of the stock is currently owned by institutional investors.

CVS Health Corporation (NYSE:CVS) traded down 0.10% during trading on Friday, reaching $86.40. 4,346,345 shares of the company were exchanged. CVS Health Corporation has a 1-year low of $85.89 and a 1-year high of $106.67. The stock has a market capitalization of $92.12 billion, a P/E ratio of 19.88 and a beta of 0.83. The company’s 50-day moving average price is $91.41 and its 200-day moving average price is $96.91.

CVS Health Corporation (NYSE:CVS) last announced its quarterly earnings results on Tuesday, August 2nd. The pharmacy operator reported $1.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.02. CVS Health Corporation had a net margin of 2.88% and a return on equity of 15.86%. The firm had revenue of $43.70 billion for the quarter, compared to the consensus estimate of $44.28 billion. During the same period in the prior year, the firm posted $1.19 earnings per share. The firm’s quarterly revenue was up 17.6% compared to the same quarter last year. On average, equities analysts forecast that CVS Health Corporation will post $5.86 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, November 3rd. Investors of record on Monday, October 24th will be issued a dividend of $0.425 per share. This represents a $1.70 dividend on an annualized basis and a yield of 1.97%. The ex-dividend date of this dividend is Thursday, October 20th. CVS Health Corporation’s dividend payout ratio (DPR) is presently 39.08%.

A number of equities research analysts have issued reports on CVS shares. Mizuho reissued a “buy” rating and set a $111.00 target price on shares of CVS Health Corporation in a report on Friday, September 30th. Morgan Stanley reissued a “hold” rating and set a $104.00 target price on shares of CVS Health Corporation in a report on Monday, September 12th. Leerink Swann reissued an “outperform” rating and set a $105.00 target price (down previously from $110.00) on shares of CVS Health Corporation in a report on Sunday, October 2nd. Credit Suisse Group AG reissued a “buy” rating and set a $115.00 target price on shares of CVS Health Corporation in a report on Tuesday, September 20th. Finally, Vetr cut shares of CVS Health Corporation from a “strong-buy” rating to a “hold” rating and set a $95.44 target price on the stock. in a report on Monday, July 25th. Six equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $112.11.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

Related posts

Leave a Comment